Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie

Read MoreHide Full Article

For Immediate Release

Chicago, IL – July 25, 2022 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: J&J (JNJ - Free Report) , Novartis (NVS - Free Report) , GSK plc (GSK - Free Report) , Merck (MRK - Free Report) and AbbVie (ABBV - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Pharma Stock Roundup: Early Q2 Earnings Are In

This week, J&J set in motion the second-quarter earnings season for the drug and biotech sector with an earnings and sales beat. Novartis reported mixed results. GSK plc completed the separation of its Consumer Healthcare segment into a new company, Haleon. Merck's head and neck cancer study on Keytruda failed while AbbVie filed a regulatory application in Europe seeking approval for its migraine candidate atogepant.

Recap of the Week's Most Important Stories

J&J Beats on Q2 Earnings & Sales, Lowers View: J&J reported better-than-expected second-quarter results as it beat estimates for both earnings and sales. Its Pharmaceuticals unit continued to do well. Its COVID-19 vaccine sales improved in the second quarter after a lower-than-expected contribution in the first quarter. Sales in the MedTech segment continued to improve. However, sales were partly hurt by COVID-related restrictions in countries like China and labor and supply constraints.

However, J&J slightly lowered its sales and profit outlook for the year due to expected currency headwinds amid a strengthening U.S. dollar.

Novartis' Mixed Q2: Novartis' second-quarter results were mixed. It missed estimates for revenues while beating the same for earnings. Sales in Innovative Medicines rose 5% at constant currency driven by the strong growth of Entresto Cosentyx, Kisqali and Zolgensma.  Sales in the Sandoz division also rose 5% as the business continued to improve from COVID impacts and returned to normal. The company maintained its guidance for sales and core operating income to grow in the mid-single-digit range in 2022.

GSK Completes Demerger of Consumer Unit: GSK completed the demerger of its Consumer Healthcare (CHC) segment into a standalone company. The independent Consumer Healthcare company has been named Haleon. Shares of Haleon have already been listed on the London Stock Exchange (LSE), which started trading on Jul 18. It is expected that American Depositary Shares. representing shares of Haleon plc, will start trading with the ticker symbol "HLN" on the NYSE in a regular way from Jul 22.

GSK also completed its share consolidation following the demerger. GSK has issued four new ordinary shares of 31.25 pence each for every five existing ordinary shares of 25 pence each. With regard to ADS issued by GSK, four new ADSs will be issued for every five existing ADSs of GSK trading on the NYSE.

AbbVie Seeks Approval for Migraine Candidate in Europe: AbbVie submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of its CGRP receptor antagonist, atogepant for the prophylaxis treatment of migraine. The application is supported by data from two pivotal phase III studies, ADVANCE and PROGRESS, which evaluated atogepant in adult patients with episodic and chronic migraine.

Atogepant is already approved in the United States as Qulipta for the preventive treatment of episodic migraine since last September. Last month, AbbVie filed for the label expansion of Qulipta in the United States as a preventive treatment for chronic migraine. However, atogepant is not yet approved for any indication in Europe.

AbbVie announced a strategic alliance with eye care solutions company, iSTAR Medical to further develop and commercialize the latter's most advanced product, MINIject, a minimally invasive glaucoma surgical device for patients with glaucoma. For the deal, AbbVie will make a $60 million upfront payment to iSTAR Medical. MINIject is already approved and launched in Europe, while in the United States, a U.S. Premarket Approval study (STAR-V) has been filed to allow commercialization.

Merck's Head and Neck Cancer Study on Keytruda Fails: Merck's phase III study evaluating Keytruda for unresected locally advanced head and neck squamous cell carcinoma (HNSCC) failed to meet its primary endpoint of event-free survival (EFS). The final analysis of the study showed that there was an improvement in EFS in patients treated with the Keytruda plus concurrent chemoradiation therapy (CRT) compared to the placebo plus CRT.

However, the data failed to meet statistical significance. Keytruda is presently approved for certain later stages of HNSCC in the United States, Europe and some other countries. The KEYNOTE-412 study was evaluating Keytruda in earlier stages of HNSCC.

The NYSE ARCA Pharmaceutical Index rose 0.4% in the last five trading sessions.

Large Cap Pharmaceuticals Industry 5YR % Return

In the last five trading sessions, Novartis rose the most (4%) while Merck declined the most (4%).

In the past six months, Lilly rose the most (36%) while Roche declined the most (12.3%).

(See the last pharma stock roundup here: MRK Buys Cancer Drug Rights, SNY Dupixent Kids Study Succeeds)

What's Next in the Pharma World?

Keep a tab on Q2 earnings of Pfizer, Merck, Sanofi, AstraZeneca and others and regular pipeline and regulatory updates next week.

Why Haven't You Looked at Zacks' Top Stocks?

Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Published in